Shijiazhuang Yiling Pharmaceutical Co., Ltd.
002603
Pozycja w akcjach
#4251
Shijiazhuang Yiling Pharmaceutical Co., Ltd. engages in the research and... Shijiazhuang Yiling Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of Chinese medicine primarily in China. It offers drugs for cardiovascular and cerebrovascular, respiratory, endocrine, neurological, digestive, immune, and urinary diseases, diabetes mellitus, oncology, sleep-improving, and anti-aging. The company also provides dietary supplements, disinfection products, personal protective equipment, as well as formula granules. Shijiazhuang Yiling Pharmaceutical Co., Ltd. was founded in 1992 and is based in Shijiazhuang, China.
Cena akcji
$2.23
Kapitalizacja rynkowa
$3.72B
Zmiana (1 dzień)
0.26%
Zmiana (1 rok)
-8.93%
Kraj
CN
Handel Shijiazhuang Yiling Pharmaceutical Co., Ltd. (002603)
Kategoria
Healthcare
Zyski dla Shijiazhuang Yiling Pharmaceutical Co., Ltd. (002603)
Zyski w Jun 2026 TTM: $246.26M
Według najnowszych raportów finansowych Shijiazhuang Yiling Pharmaceutical Co., Ltd., obecny zysk firmy wynosi $246.26M. W roku 2023 firma osiągnęła zysk w wysokości $237.93M, spadek w porównaniu do zysku z roku 2022, który wynosił $403.11M. Wyświetlany zysk to zysk przed odsetkami i podatkami, czyli EBIT.
Historia zysków firmy Shijiazhuang Yiling Pharmaceutical Co., Ltd. od 2008 do 2026
Zyski na koniec każdego roku
| Rok | Zyski | Zmień |
|---|---|---|
| 2026 (TTM) | $246.26M | -324.63% |
| 2024 | $-109.63M | -146.08% |
| 2023 | $237.93M | -40.98% |
| 2022 | $403.11M | 64.90% |
| 2021 | $244.45M | 12.26% |
| 2020 | $217.75M | 114.19% |
| 2019 | $101.66M | -0.25% |
| 2018 | $101.91M | 3.87% |
| 2017 | $98.11M | 8.63% |
| 2016 | $90.32M | 17.44% |
| 2015 | $76.90M | 16.02% |
| 2014 | $66.28M | 38.96% |
| 2013 | $47.70M | 37.56% |
| 2012 | $34.68M | -58.95% |
| 2011 | $84.47M | 51.19% |
| 2010 | $55.87M | 7.65% |
| 2009 | $51.90M | 145.52% |
| 2008 | $21.14M | 0.00% |
Zyski podobnych firm lub konkurentów
| Firma | Zyski | Różnica w zyskach | Kraj |
|---|---|---|---|
| $1.35B | 448.16% |
US
|
|
| - | - |
SE
|
|
| - | - |
FR
|
|
| - | - |
IT
|
|
| $26.37M | -89.29% |
US
|
